Health Catalyst, Inc. HCAT

What a time it’s been for Health Catalyst. In the past six months alone, the company’s stock price has increased by a massive 48.7%, reaching $1.76 per share. This performance may have investors wondering how to approach the situation.

Software is eating the world, and virtually no business is left untouched by it. The undeniable tailwinds fueling the industry have also led to strong returns for SaaS stocks lately as they’ve gained 47.2% over the past six months, outpacing the S&P 500’s 21.4% rise.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Health Catalyst is back in focus after analysts revised fair value from about US$2.10 to roughly US$1.83 per share, which points to a more cautious stance on the stock. Recent research has shifted from earlier optimism with price targets in the US$2 to US$3 range to current levels closer to US$1.80, as analysts weigh execution risks around churn, divestitures and the durability of growth in its health technology offerings. In this article, you will see how these changing targets fit into the...

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

The population health management market is projected to grow from USD 46.93 billion in 2026 to USD 98.41 billion by 2031, registering a 16.0% CAGR. Growth is driven by value-based care, chronic disease prevalence, cost reduction, and demand for improved patient outcomes. Software led the market in 2025, while cloud-based PHM solutions are set to grow fastest, supported by AI, predictive analytics, remote patient monitoring, and interoperable data. Asia Pacific is expected to record the highest C

SALT LAKE CITY, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that on September 14, 2026, the Compensation Committee of the Company’s Board of Directors granted 2,747,385 restricted stock units (the “RSUs”) to Simeon Kohl under the Health Catalyst, Inc. 2026 Employment Inducement Incentive Plan (the “Inducement Plan”) i

Health Catalyst, Inc. ("Health Catalyst", NASDAQ: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Tami Reller has been appointed to its board of directors (Board), effective October 1, 2026. Reller will serve as audit chair and as a member of its compensation committee, also effective October 1, 2026.

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

The data analytics company has cycled through three CEOs in eight months. Health Catalyst is betting its newest chief can navigate an AI pivot and revenue headwinds.

Kohl brings public-company leadership and a record of successful transformation; Ben Albert to continue as Chief Business OfficerSALT LAKE CITY, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Simeon Kohl has been appointed Chief Executive Officer (CEO) and President and a member of the Company’s Board of Directors,

SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the 2026 Wells Fargo Healthcare Conference, taking place in Boston, on Wednesday, September 9, 2026 and Thursday, September 10, 2026. About Health Catalyst Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence c

A number of stocks fell in the afternoon session after Bloomberg reported that Anthropic’s preliminary second-quarter revenue topped $11.5 billion.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Health Catalyst’s second quarter was marked by a notable decline in sales, which management attributed primarily to the ongoing impact of client migrations and a reduction in lower-margin services. The company’s decision to divest Vitalware, its revenue cycle management business, was described by CEO Ben Albert as necessary to focus on areas of highest conviction, despite the near-term revenue impact. Albert acknowledged the structural challenges facing health systems and emphasized that the div

Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 12.7% year on year to $70.49 million. On the other hand, next quarter’s revenue guidance of $55.5 million was less impressive, coming in 10.7% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.

Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 23.1% in the afternoon session after the company provided a weak third-quarter revenue forecast and lowered its full-year outlook, despite topping second-quarter revenue expectations.

Moby summary of Health Catalyst, Inc.'s Q2 2026 earnings call